The company continues to operate without revenue, reporting a $5.7 million operating loss in 2026Q1 driven by escalating R&D expenditures.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 876 | 1.78K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -876 | -1.78K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 50.75% | 0% | 0% | 0% | -0.08% | -0.06% | 0% | 0% | - |
| Operating Expenses | 21.89M | 19.45M | 17.63M | 9.32M | 8.04M | 4.59M | 1.86M | 3.42M | 1.69M | 1.57M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.36M | 2.23M | 2.15M | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 15.76M | 17.22M | 15.48M | 7.7M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -21.89M | -19.45M | -17.64M | -9.33M | -8.04M | -4.6M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -10.27% | -89.08% | -16.01% | -74.87% | -146.7% | 45.59% | -102.72% | -7.38% | - |
| EBITDA | -21.78M | -19.45M | -17.63M | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -34.1% | -10.28% | -89.12% | -16.02% | -74.93% | -146.98% | 45.64% | -102.94% | -7.4% | - |
| D&A (Non-Cash Add-back) | 876 | 1.78K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBIT | -21.76M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Interest Income | 134.35K | 89.7K | 223.01K | 436.06K | 215.02K | 27.37K | 832 | 0 | 0 | 0 |
| Interest Income | 134.35K | 89.7K | 223.01K | 436.06K | 215.02K | 27.37K | 832 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 134.35K | 89.7K | 223.01K | 436.06K | 215.02K | 27.37K | 832 | 0 | 0 | 0 |
| Pretax Income | -21.76M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0% |
| Net Income | -21.76M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -35.47% | -11.16% | -95.85% | -13.63% | -71.21% | -145.45% | 45.64% | -102.72% | -7.38% | - |
| Net Income (Continuing) | -21.76M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.49 | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Growth % | -24.6% | -18.18% | -75.36% | -13.11% | -74.29% | -133.33% | 48.28% | -107.14% | -7.69% | - |
| EPS (Basic) | - | -1.43 | -1.21 | -0.69 | -0.61 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Diluted Shares Outstanding | 14.57M | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M | 12.7M | 11.74M | 11.97M | 11.74M |
| Basic Shares Outstanding | 14.57M | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M | 12.7M | 11.74M | 11.97M | 11.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Critical Liquidity and Dilution
As indicated by the most recent quarterly data, Greenwich LifeSciences reported R&D expenditures of $5.2 million, reflecting a significant uptick in clinical trial activity that continues to outpace the company's ability to generate any meaningful revenue or offset operational costs through commercial activities.
The company's cost structure is entirely dominated by clinical development, with R&D spending showing high volatility as the FLAMINGO-01 trial progresses. This reliance on heavy R&D investment without a corresponding revenue stream suggests that the firm remains in a high-risk phase where operational discipline is secondary to trial completion.
According to the provided financial statements, the company recorded $1.5 million in stock-based compensation during 2026Q1, a figure that highlights the reliance on equity-based incentives to preserve cash while simultaneously increasing the potential for future shareholder dilution in a pre-revenue environment.
The consistent use of stock-based compensation appears to be a strategic lever to manage cash outflows, yet it obscures the true economic cost of operations for investors. This practice warrants further investigation into the long-term impact on EPS dilution, especially given the company's current negative cash position.
Based on reported figures, the company's operating losses reached $5.7 million in 2026Q1, underscoring a structural inability to achieve operating leverage while the firm remains entirely dependent on external capital to fund its ongoing clinical development and administrative overhead requirements.
The lack of revenue generation means that every dollar spent on SG&A and R&D flows directly to the bottom line as a loss, preventing any possibility of scaling efficiency. Investors should monitor the widening gap between operating expenses and the company's ability to secure non-dilutive funding.
As highlighted by the reported negative cash balance of approximately $6.7 million, the company faces a precarious financial situation that may necessitate immediate dilutive financing, potentially undermining the value proposition for existing shareholders if the FLAMINGO-01 trial fails to meet its primary endpoints.
Short-sellers would likely focus on the company's inability to maintain a positive cash balance and the binary nature of its single-asset pipeline. The reliance on a specific HLA-A02 patient subset for efficacy creates a narrow margin for error that could lead to significant valuation volatility.
Quick answers to the most common questions about buying GLSI stock.
For fiscal year 2025, Greenwich LifeSciences, Inc. (GLSI) reported total revenue of $0.0M.
Greenwich LifeSciences, Inc. (GLSI) reported a net loss of $19.4M for the fiscal year ending 2025.